Similar to the results observed in the subcutaneous xenograft model, the mCAR-T (10) group had more CD3+ and Granzyme B+ cells in the tumors, reduced CD133 expression, and increased PD-L1 expression in the tumor cells compared to the CAR-T group (Figure 7D and 7E). This evidence concerns the gene PROM1 and neoplasm.